For active substances in agrochemicals and biocides, 5 batch analysis provides evidence that the substance placed before authorities is chemically defined, reproducible and controlled across production. It supports authorisation and technical equivalence by showing what the active substance contains, how pure it is and whether the composition remains consistent from batch to batch.
Triskelion conducts 5 batch analyses for active substances and supports clients in connecting the analytical results to the regulatory question behind the dossier. The value of the work sits in the full chain, from choosing the right analytical scope to interpreting the data in the context of authorisation or technical equivalence.
If you are preparing an active substance dossier or need to assess technical equivalence, the analytical scope should be clear before testing starts. Discuss what this means for your situation with Isabel Van Laanen at isabel.vanlaanen@triskelion.
A 5 batch analysis examines five representative batches of an active substance. The analysis is used to establish minimum purity, the chemical fingerprint of the substance and the consistency of its composition across batches. For active substances, this is a central part of demonstrating that the material is sufficiently characterised for regulatory review.
The analysis also helps identify and quantify relevant impurities. These impurities can influence the regulatory assessment, particularly when they have toxicological relevance or when their presence differs between production routes. A single batch can show what was present in one production run. Five batches provide a broader picture of the substance as it is manufactured.
For companies preparing an application, the question is therefore not simply whether the active substance can be analysed. The more relevant question is whether the data package can support the regulatory decision that needs to be made.
In both agrochemicals and biocides, active substance dossiers require data that allow authorities to assess identity, purity and impurity profile. 5 batch analysis is used to support that assessment before authorisation.
The same principle applies in technical equivalence cases. When an active substance is produced by another manufacturer, at another site or through another production process, the new source must be compared with the already approved reference substance. The 5 batch data help demonstrate whether the new source remains within the accepted limits of that reference substance.
The exact regulatory route and data expectations depend on the product category, the substance, the production process and the authority involved. That is why the analytical plan should be aligned with the dossier strategy before testing starts.
5 batch analysis is relevant when a company prepares an active substance dossier for agrochemicals or biocides. It is also relevant when a company wants to demonstrate technical equivalence for an active substance from a different manufacturer, location or production process.
It may also become relevant after changes in manufacturing. A change in raw materials, production site, process conditions or supplier can affect the impurity profile or consistency of the active substance. In those cases, analytical data can help determine whether the existing regulatory position still holds or whether additional justification is needed.
The earlier this is assessed, the easier it becomes to avoid unnecessary testing, unclear results or later discussion about whether the data answer the right regulatory question.
Triskelion supports clients with the analytical work and the interpretation needed around 5 batch analysis. This starts with understanding the regulatory purpose of the analysis. An authorisation dossier, a technical equivalence assessment and a manufacturing change can require a different analytical scope.
Based on that scope, Triskelion performs the relevant analyses to determine purity, chemical profile and batch consistency. Where required, the work includes impurity profiling and comparison of results across the five batches. The outcome is reported in a way that supports regulatory review and internal decision making.
Because Triskelion combines laboratory analysis with regulatory consultancy, clients can discuss the analytical results in the context of the dossier. That helps prevent a common problem in technical data packages: results that are analytically correct, while still leaving the regulatory question insufficiently answered.
The method and performance specifications for 5 batch analysis depend on the active substance, the expected impurity profile, the matrix and the regulatory purpose of the study. There is no single fixed LOQ, LOD or recovery range that applies to every active substance.
For each project, Triskelion defines the analytical approach before testing starts. Relevant performance parameters, such as LOQ, LOD, recovery and selectivity, are confirmed in relation to the substance and the required reporting level. This makes the method fit for the question the dossier needs to answer.
Where existing validated methods are available, they can be used or adapted within the applicable quality framework. Where additional method development is needed, this is discussed before the analytical programm begins.
5 batch analysis is the analytical assessment of five representative batches of an active substance. It is used to establish identity, minimum purity, impurity profile and consistency across production batches.
5 batch analysis is relevant for active substance authorisation and technical equivalence in agrochemicals and biocides. The exact requirement depends on the regulatory route, the active substance and the authority reviewing the dossier.
For biocides, 5 batch analysis is part of the data used to support active substance assessment and technical equivalence. In technical equivalence, the analytical profile of representative batches helps compare a new source with the approved reference source.
For agrochemicals, batch analysis data support the characterisation of the active substance. The analysis helps establish the content of the active ingredient and relevant impurities in representative production batches.
It shows minimum purity, chemical identity, impurity profile and consistency across five representative batches. This helps authorities assess whether the active substance is sufficiently characterised and reproducible.
One batch shows what was present in one production run. Five representative batches provide a stronger basis for assessing whether the active substance is manufactured consistently and whether the impurity profile remains controlled.
In technical equivalence, 5 batch data are used to compare an active substance from another source with the already approved reference substance. The comparison focuses on identity, purity, impurity profile and whether the new source remains within the accepted limits.
It can. A different manufacturer, production location or production process can change the composition or impurity profile of the active substance. In those cases, technical equivalence may need to be assessed before the substance can be relied on in the same regulatory context.
If you are preparing an active substance dossier or need to assess technical equivalence, the analytical scope should be clear before testing starts. Discuss what this means for your situation with Isabel Van Laanen at isabel.vanlaanen@triskelion.
